Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
New analytical tool could lead to a cure for idiopathic pulmonary fibrosis

New analytical tool could lead to a cure for idiopathic pulmonary fibrosis

Newly identified stem cell variants drive inflammation in cystic fibrosis patients

Newly identified stem cell variants drive inflammation in cystic fibrosis patients

Stem cells can be used to repair damaged lung tissue in COPD patients

Stem cells can be used to repair damaged lung tissue in COPD patients

The standard of care and recent advancements in the control of skin inflammation

The standard of care and recent advancements in the control of skin inflammation

Insilico Medicine uses AI to discover novel SIK2 inhibitors

Insilico Medicine uses AI to discover novel SIK2 inhibitors

Human senescent fibroblasts trigger fibrogenic reaction in the lungs of immunodeficient mice

Human senescent fibroblasts trigger fibrogenic reaction in the lungs of immunodeficient mice

Addressing research gaps: The UK's efforts to study lung cancer in never smokers

Addressing research gaps: The UK's efforts to study lung cancer in never smokers

3D-printed vaginal ovules offer promising treatment for endometriosis

3D-printed vaginal ovules offer promising treatment for endometriosis

Insilico announces new multimodal transformer-based aging clock for processing diverse data sets

Insilico announces new multimodal transformer-based aging clock for processing diverse data sets

Unraveling the complexity of 'Long-COVID' and its impact on breathing

Unraveling the complexity of 'Long-COVID' and its impact on breathing

Newly discovered molecule effectively destroys senescent cells

Newly discovered molecule effectively destroys senescent cells

University Hospitals Birmingham partners with Qureight for lung disease research

University Hospitals Birmingham partners with Qureight for lung disease research

Researchers identify a major stem cell variant in lungs of patients with idiopathic pulmonary fibrosis

Researchers identify a major stem cell variant in lungs of patients with idiopathic pulmonary fibrosis

Protein inhibition could offer new strategies for treating severe asthma

Protein inhibition could offer new strategies for treating severe asthma

New type of nanoparticle can deliver messenger RNA encoding useful proteins to the lungs

New type of nanoparticle can deliver messenger RNA encoding useful proteins to the lungs

Study reveals synergistic impact of estrogen and intestinal dysbiosis on pulmonary fibrosis

Study reveals synergistic impact of estrogen and intestinal dysbiosis on pulmonary fibrosis

Chest CT reveals persistent lung abnormalities in patients two years post-COVID

Chest CT reveals persistent lung abnormalities in patients two years post-COVID

Scientists discover a protein in the lung that blocks SARS-CoV-2 infection

Scientists discover a protein in the lung that blocks SARS-CoV-2 infection

A review of innate immunity relevant to SARS-CoV-2 and COVID-19

A review of innate immunity relevant to SARS-CoV-2 and COVID-19

Aston University scientists team up with Isterian Biotech to develop novel drugs to treat fibrotic diseases

Aston University scientists team up with Isterian Biotech to develop novel drugs to treat fibrotic diseases